In her latest bid to address prescription drug prices, U.S. Sen. Elizabeth Warren (D-Mass.) is urging the U.S. Federal Trade Commission to “closely scrutinize”
Tag - STAT+
Amid ongoing controversy over clinical trial transparency, a new analysis found that results of 43 studies involving thousands of children were never reported
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s CEO, Chris Viehbacher described the commercial launches this year of an
SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies to treat autoimmune diseases and cancer, is now planning to cut
Good morning, everyone, and welcome to a new year. We hope the holiday respite was refreshing and inspiring, because that oh-so-familiar routine of online
WASHINGTON — The Food and Drug Administration’s review and approval of a controversial Alzheimer’s drug was “rife with irregularities,” including dozens of
The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000 a year to be cost-effective, according to a draft analysis from
California authorities are seeking to revoke a license held by a CVS Health mail-order pharmacy unit for violating several state laws that govern shipments of
Bay Area biotech Guardant Health on Thursday announced results from a massive trial of its blood-based test for the early detection of colon cancer that, while
Virtual reality startups BehaVR and OxfordVR have merged and raised $13 million in Series B funding to develop treatments for anxiety and chronic pain that
